
The flexible dosing schedule has been approved for patients with skin, lung and cervical cancer

This rare, chronic autoimmune disease can cause kidney failure if left untreated

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

The results from a global phase 3 trial show the longest survival data ever reported in this setting

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

This is the first and only at-home subcutaneous treatment option for this disease

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

The new building is part of a 1.5bn euro site investment

Approximately 160,000 people are diagnosed with this aggressive form of cancer each year